Literature DB >> 27447170

The use of finite element analysis to estimate the changing strength of bone following treatment for osteoporosis.

D B Burr1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27447170     DOI： 10.1007/s00198-016-3707-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  10 in total

1.  Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.

Authors:  Ken Iwata; Jiliang Li; Helene Follet; Roger J Phipps; David B Burr
Journal:  Bone       Date:  2006-06-27       Impact factor: 4.398

2.  Proposed pathogenesis for atypical femoral fractures: lessons from materials research.

Authors:  B Ettinger; D B Burr; R O Ritchie
Journal:  Bone       Date:  2013-02-16       Impact factor: 4.398

3.  Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs.

Authors:  David B Burr; Ziyue Liu; Matthew R Allen
Journal:  Bone       Date:  2014-10-23       Impact factor: 4.398

4.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

5.  The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro.

Authors:  Felix Peter Koch; Sareh Said Yekta; Christina Merkel; Thomas Ziebart; Ralf Smeets
Journal:  Head Face Med       Date:  2010-07-09       Impact factor: 2.151

Review 6.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

7.  Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.

Authors:  J Ward; C Wood; K Rouch; D Pienkowski; H H Malluche
Journal:  Osteoporos Int       Date:  2016-07-22       Impact factor: 4.507

8.  Incidence of atypical nontraumatic diaphyseal fractures of the femur.

Authors:  Richard M Dell; Annette L Adams; Denise F Greene; Tadashi T Funahashi; Stuart L Silverman; Eric O Eisemon; Hui Zhou; Raoul J Burchette; Susan M Ott
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

9.  Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.

Authors:  Aymen I Idris; Javier Rojas; Iain R Greig; Rob J Van't Hof; Stuart H Ralston
Journal:  Calcif Tissue Int       Date:  2008-02-08       Impact factor: 4.333

10.  Inhibition of osteoblast function in vitro by aminobisphosphonates.

Authors:  Isabel R Orriss; Michelle L Key; Kay W Colston; Timothy R Arnett
Journal:  J Cell Biochem       Date:  2009-01-01       Impact factor: 4.429
  10 in total
  1 in total

1.  Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.

Authors:  Sanchita Agarwal; Elizabeth Shane; Thomas Lang; Stephanie Shiau; Mafo Kamanda-Kosseh; Mariana Bucovsky; Joan M Lappe; Julie Stubby; Robert R Recker; Yizhong Hu; Zexi Wang; X Edward Guo; Adi Cohen
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.